NuScale's $985M Raise Highlights Cash Cushion but No Revenue

What happened

NuScale Power raised $985 million through common stock issuance in the first half of 2026, ending Q2 with approximately $1.1 billion in cash and short-term investments, but generated only $75,000 of revenue and a $65 million operating loss for the quarter. The company's operating cash burn remains severe, with first-half 2026 operating cash outflow of $372.9 million, including a $259.9 million payment to ENTRA1 under the Project Master Agreement, while no binding power purchase or module delivery contract has been signed. The market has responded by cutting NuScale's stock price by over 70% from its 2025 high, valuing the company at roughly $2.9 billion despite minimal revenue and a multiyear path to commercialization. Management stated that current liquidity, together with access to capital markets, is sufficient for at least the next 12 months, but the runway depends on continued equity issuance, which has already increased Class A shares outstanding to 410.4 million from 318.5 million at year-end 2025. The recent article highlights this tension, noting that while the cash pile provides a buffer, the absence of binding customer commitments raises doubts about how long the company can sustain its pre-revenue operations without further dilution.

Implication

The large equity raise shows that the market is willing to fund NuScale's pre-revenue phase, but it also signals that dilution risk is a persistent headwind for existing shareholders. The lack of binding customer contracts, especially the non-binding TVA collaboration and stalled Romania financing, means that the company's cash runway is not matched by a clear path to revenue generation in the near term. Investors should focus on the next 3-6 months for any signs of contract conversion, as the analyst view remains WAIT with no margin of safety at current prices and an attractive entry point around $8. The PMA obligations are a concerning cash drain, with $259.9 million already paid in H1 2026 and potential future milestone payments that are not contingent on revenue, which could accelerate dilution if no binding off-take emerges. Overall, the news does not change the thesis that NuScale is a high-risk, high-reward story hinging on commercialization; until a definitive PPA or pre-EPC contract is announced, investors should maintain a cautious stance and look for a lower entry or a clear catalyst.

Thesis delta

No major shift in thesis; the article confirms the pre-revenue status and highlights the cash cushion, but the core investment thesis remains unchanged: value hinges on binding off-take contracts. The only delta is a slight reinforcement of the dilution risk and cash burn concerns, which supports maintaining the WAIT rating and focus on near-term commercialization checkpoints.